Oral oncology最新文献

英文中文

Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study 肺部免疫预后指数与接受免疫疗法的复发性或转移性鼻咽癌（R/M）的临床预后有关：多中心、单臂、2 期研究的结果

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-18 DOI: 10.1016/j.oraloncology.2024.107028

Yu Min , Xiaoxia Liu , Zhigong Wei , Ge Song , Yuantai Li , Kun Gao , Zheran Liu , Yiyan Pei , Huilin Li , Junyou Ge , Yan Qing , Youneng Wei , Xingchen Peng

Background

Immune-related biomarkers are linked to the outcomes of cancer immunotherapy. This study evaluates the baseline and longitudinal association between the lung immune prognostic index (LIPI) and immune checkpoint inhibitor outcomes in previously treated recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) patients.

Methods

Data from 153 R/M NPC patients (median age = 49.00 years old) enrolled in a multicenter, single-arm, phase 2 study (NCT03848286) were analyzed. Pretreatment LIPI was classified into good and intermediate/poor (inter/poor) groups. Longitudinal LIPI variations were categorized into “Stable good”, “Trend to increase”, “Trend to decrease”, and “Stable inter/poor”. Primary and secondary outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR).

Results

Pretreatment LIPI was significantly associated with OS (inter/poor vs. good: HR = 2.54, 95 % CI: 1.60–4.04, P < 0.001), PFS [inter/poor vs. good: hazard ratio (HR) = 2.18, 95 % CI: 1.47–3.23, P < 0.001], and DCR [inter/poor vs. good: odd ratio (OR) = 0.26, 95 % CI: 0.12–0.58, P < 0.001)]. Patients with persistently inter/poor LIPI status showed worse OS (HR = 3.25, 95 % CI: 1.84–5.74, P < 0.001), PFS (HR = 2.96, 95 % CI: 1.85–4.74, P < 0.001), and ORR (OR = 0.21, 95 % CI: 0.08–0.56, P < 0.001) compared to the persistently good subgroup.

Conclusion

Pretreatment LIPI and its longitudinal variations may serve as potential biomarkers for predicting immune checkpoint inhibitor outcomes in R/M NPC patients.

背景免疫相关生物标志物与癌症免疫疗法的结果有关。本研究评估了既往接受过治疗的复发性或转移性（R/M）鼻咽癌（NPC）患者的肺免疫预后指数（LIPI）与免疫检查点抑制剂疗效之间的基线和纵向关联。方法分析了一项多中心、单臂、2期研究（NCT03848286）中入组的153名R/M NPC患者（中位年龄=49.00岁）的数据。治疗前 LIPI 分为良好组和中间/差（中间/差）组。LIPI的纵向变化分为 "稳定良好组"、"趋势增加组"、"趋势减少组 "和 "稳定中间/差组"。主要和次要结果为总生存期（OS）、无进展生存期（PFS）、客观反应率（ORR）和疾病控制率（DCR）。治疗前 LIPI 与 OS（贫间期与良期：HR = 2.54，95 % CI：1.60-4.04，P < 0.001）、PFS [贫间期与良期：危险比 (HR) = 2.18，95 % CI：1.47-3.23，P < 0.001]和 DCR [贫间期与良期：奇数比 (OR) = 0.26，95 % CI：0.12-0.58，P < 0.001]显著相关。］LIPI 状态持续为间/差的患者的 OS（HR = 3.25，95 % CI：1.84-5.74，P < 0.001）、PFS（HR = 2.96，95 % CI：1.85-4.74，P < 0.001）和 ORR（OR = 0.21，95 % CI：0.08-0.56，P < 0.001）。结论治疗前 LIPI 及其纵向变化可作为预测 R/M NPC 患者免疫检查点抑制剂预后的潜在生物标志物。

{"title":"Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study","authors":"Yu Min , Xiaoxia Liu , Zhigong Wei , Ge Song , Yuantai Li , Kun Gao , Zheran Liu , Yiyan Pei , Huilin Li , Junyou Ge , Yan Qing , Youneng Wei , Xingchen Peng","doi":"10.1016/j.oraloncology.2024.107028","DOIUrl":"10.1016/j.oraloncology.2024.107028","url":null,"abstract":"<div><h3>Background</h3><p>Immune-related biomarkers are linked to the outcomes of cancer immunotherapy. This study evaluates the baseline and longitudinal association between the lung immune prognostic index (LIPI) and immune checkpoint inhibitor outcomes in previously treated recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) patients.</p></div><div><h3>Methods</h3><p>Data from 153 R/M NPC patients (median age = 49.00 years old) enrolled in a multicenter, single-arm, phase 2 study (NCT03848286) were analyzed. Pretreatment LIPI was classified into good and intermediate/poor (inter/poor) groups. Longitudinal LIPI variations were categorized into “Stable good”, “Trend to increase”, “Trend to decrease”, and “Stable inter/poor”. Primary and secondary outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR).</p></div><div><h3>Results</h3><p>Pretreatment LIPI was significantly associated with OS (inter/poor vs. good: HR = 2.54, 95 % CI: 1.60–4.04, P < 0.001), PFS [inter/poor vs. good: hazard ratio (HR) = 2.18, 95 % CI: 1.47–3.23, P < 0.001], and DCR [inter/poor vs. good: odd ratio (OR) = 0.26, 95 % CI: 0.12–0.58, P < 0.001)]. Patients with persistently inter/poor LIPI status showed worse OS (HR = 3.25, 95 % CI: 1.84–5.74, P < 0.001), PFS (HR = 2.96, 95 % CI: 1.85–4.74, P < 0.001), and ORR (OR = 0.21, 95 % CI: 0.08–0.56, P < 0.001) compared to the persistently good subgroup.</p></div><div><h3>Conclusion</h3><p>Pretreatment LIPI and its longitudinal variations may serve as potential biomarkers for predicting immune checkpoint inhibitor outcomes in R/M NPC patients.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"159 ","pages":"Article 107028"},"PeriodicalIF":4.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142243761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on “The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-) radiotherapy” 关于 "确定性（化疗）放疗后喉癌和下咽癌图像识别结节外扩展的预后价值 "的评论

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-17 DOI: 10.1016/j.oraloncology.2024.107035

Gayathri Rengasamy, Vishnu Priya Veeraraghavan

引用次数: 0

Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma 经过精心挑选的口咽鳞癌患者接受经口机器人手术（TORS）后可早日重返工作岗位

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-17 DOI: 10.1016/j.oraloncology.2024.107032

Lorne Green , Lachlan McDowell , Fiona Ip , Mario Tapia , Meiling Zhou , Michael T. Fahey , Benjamin Dixon , Matthew Magarey

Introduction

The aims of this study were to investigate the rate and time to return to work (RTW) after transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC) and to explore the impact of disease or work-related factors leading to variations in RTW outcomes.

Methods

Cross-sectional survey of disease, socioeconomic, work-related and health-related quality of life (HR-QOL). Qualitative analysis of responses for facilitators and barriers to RTW.

Results

A total of 47 participants employed at diagnosis were included in the study, with an average age 56 years. Median survey time 3.2 years. 22 participants underwent TORS only with 25 undergoing TORS with adjuvant therapy. 93.6 % had stage 1 disease. 95.7 % of participants RTW after TORS with a mean time of 13.6 weeks. Patients returned earlier after TORS alone compared to those requiring adjuvant treatment (10 weeks vs. 17 weeks; p = 0.13) Overall high HR-QOL metrics for all patients, with those undergoing adjuvant having significantly poorer outcomes for the dry mouth/sticky saliva (9.1 vs 41.3, p=<0.001) items. Qualitative analysis of free text responses showed facilitators and barriers to RTW fell under four main categories: physical, phycological/emotional, financial and workplace.

Conclusion

High rate of RTW amongst patients after TORS, which is the highest reported amongst head and neck cancer literature to date. Participants returned earlier after surgery only compared to adjuvant treatment, but both groups reported high HR-QOL metrics. Physical effects of treatment, including fatigue and oral dysfunction were some of the main barriers to RTW; whereas flexible working arrangements and support from employer/colleagues were major facilitators.

引言本研究旨在调查口咽鳞状细胞癌（OPSCC）经口机器人手术（TORS）后重返工作岗位（RTW）的比例和时间，并探讨疾病或工作相关因素对RTW结果差异的影响。结果共有 47 名确诊时已就业的参与者参与研究，平均年龄 56 岁。调查时间中位数为 3.2 年。22 名参与者仅接受了 TORS，25 名接受了 TORS 和辅助治疗。93.6%的患者病情为 1 期。95.7%的患者在接受 TORS 治疗后能够继续工作，平均时间为 13.6 周。与需要辅助治疗的患者相比，仅接受 TORS 治疗的患者复诊时间更早（10 周 vs. 17 周；p=0.13）。所有患者的 HR-QOL 指标总体较高，接受辅助治疗的患者在口干/唾液粘稠项目上的结果明显较差（9.1 vs. 41.3，p=<0.001）。对自由文本回答的定性分析显示，复工的促进因素和障碍主要分为四类：身体、生理/情感、经济和工作场所。与辅助治疗相比，仅在手术后患者就能更早地重返工作岗位，但两组患者的 HR-QOL 指标都很高。治疗对身体的影响，包括疲劳和口腔功能障碍，是复工的一些主要障碍；而灵活的工作安排和雇主/同事的支持则是复工的主要促进因素。

{"title":"Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma","authors":"Lorne Green , Lachlan McDowell , Fiona Ip , Mario Tapia , Meiling Zhou , Michael T. Fahey , Benjamin Dixon , Matthew Magarey","doi":"10.1016/j.oraloncology.2024.107032","DOIUrl":"10.1016/j.oraloncology.2024.107032","url":null,"abstract":"<div><h3>Introduction</h3><p>The aims of this study were to investigate the rate and time to return to work (RTW) after transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC) and to explore the impact of disease or work-related factors leading to variations in RTW outcomes.</p></div><div><h3>Methods</h3><p>Cross-sectional survey of disease, socioeconomic, work-related and health-related quality of life (HR-QOL). Qualitative analysis of responses for facilitators and barriers to RTW.</p></div><div><h3>Results</h3><p>A total of 47 participants employed at diagnosis were included in the study, with an average age 56 years. Median survey time 3.2 years. 22 participants underwent TORS only with 25 undergoing TORS with adjuvant therapy. 93.6 % had stage 1 disease. 95.7 % of participants RTW after TORS with a mean time of 13.6 weeks. Patients returned earlier after TORS alone compared to those requiring adjuvant treatment (10 weeks vs. 17 weeks; p = 0.13) Overall high HR-QOL metrics for all patients, with those undergoing adjuvant having significantly poorer outcomes for the dry mouth/sticky saliva (9.1 vs 41.3, p=<0.001) items. Qualitative analysis of free text responses showed facilitators and barriers to RTW fell under four main categories: physical, phycological/emotional, financial and workplace.</p></div><div><h3>Conclusion</h3><p>High rate of RTW amongst patients after TORS, which is the highest reported amongst head and neck cancer literature to date. Participants returned earlier after surgery only compared to adjuvant treatment, but both groups reported high HR-QOL metrics. Physical effects of treatment, including fatigue and oral dysfunction were some of the main barriers to RTW; whereas flexible working arrangements and support from employer/colleagues were major facilitators.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"159 ","pages":"Article 107032"},"PeriodicalIF":4.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142243760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to: Letter to the editor regarding, “Beneath the surface: A systematic review on intraoperative imaging techniques for deep margin assessment in oral squamous cell carcinoma” 回应致编辑的信，内容涉及 "表面之下：用于口腔鳞状细胞癌深部边缘评估的术中成像技术系统综述

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-16 DOI: 10.1016/j.oraloncology.2024.107034

C.M.E.M. Adriaansens, K.J. de Koning, R. Noorlag, R. de Bree, R.J.J. van Es

引用次数: 0

L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration 姜黄素类似物 L48H37 可抑制基质金属蛋白酶-9 的表达和活性，从而阻碍鼻咽癌细胞迁移

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-15 DOI: 10.1016/j.oraloncology.2024.107038

Yen-Ting Lu , Chiao-Wen Lin , Shih-Chi Su , Yu-Ting Ho , Fang-Ling Yeh , Chung-Han Hsin , Shun-Fa Yang

Objective

Metastatic disease is a major issue of treatment failure in nasopharyngeal carcinoma (NPC) patients and often linked to high mortality. L48H37, a synthetic analog of curcumin with augmented bioavailability over its parent compound, has demonstrated several oncostatic characteristics. This study was aimed to explore the anti-metastatic effect of L48H37 on NPC cancer cells and its underlying mechanism.

Methods

Cell viability was evaluated using MTT assay. Regulation of signaling pathways was elucidated by immunoblotting, and specific kinase inhibitors.

Results

In this study, we showed that L48H37 suppressed TPA-stimulated invasive and migratory capacities of NPC cell lines and gave rise to very little cytotoxic responses. Such anti-cancer effect of L48H37 was accompanied with attenuated expression levels and enzymatic activities of matrix metalloproteinase-9 (MMP-9), a pivotal mediator of metastatic processes. In addition, L48H37 interfered with TPA-induced JNK activation, and the treatment of L48H37 combined with a JNK antagonist demonstrated a synergistic effect on restraining TPA-stimulated MMP-9 activity and migration events in NPC cells.

Conclusions

Our results revealed that L48H37 impeded the invasive potential of NPC cells via impairment of MMP-9 function and abundance, highlighting possible complementary therapies using curcumin or its effective analogs to manage NPC dissemination.

目标转移性疾病是鼻咽癌（NPC）患者治疗失败的一个主要问题，通常与高死亡率有关。L48H37 是姜黄素的合成类似物，与母体化合物相比生物利用度更高，具有多种抗癌特性。本研究旨在探讨 L48H37 对鼻咽癌细胞的抗转移作用及其内在机制。结果在这项研究中，我们发现 L48H37 抑制了 TPA 刺激的鼻咽癌细胞株的侵袭和迁移能力，并产生了极少的细胞毒性反应。L48H37 的这种抗癌作用伴随着基质金属蛋白酶-9（MMP-9）表达水平和酶活性的降低，MMP-9 是转移过程的关键介质。此外，L48H37 还能干扰 TPA 诱导的 JNK 激活，而且 L48H37 与 JNK 拮抗剂联合治疗对抑制 TPA 刺激的 MMP-9 活性和鼻咽癌细胞的迁移事件具有协同作用。

{"title":"L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration","authors":"Yen-Ting Lu , Chiao-Wen Lin , Shih-Chi Su , Yu-Ting Ho , Fang-Ling Yeh , Chung-Han Hsin , Shun-Fa Yang","doi":"10.1016/j.oraloncology.2024.107038","DOIUrl":"10.1016/j.oraloncology.2024.107038","url":null,"abstract":"<div><h3>Objective</h3><p>Metastatic disease is a major issue of treatment failure in nasopharyngeal carcinoma (NPC) patients and often linked to high mortality. L48H37, a synthetic analog of curcumin with augmented bioavailability over its parent compound, has demonstrated several oncostatic characteristics. This study was aimed to explore the anti-metastatic effect of L48H37 on NPC cancer cells and its underlying mechanism.</p></div><div><h3>Methods</h3><p>Cell viability was evaluated using MTT assay. Regulation of signaling pathways was elucidated by immunoblotting, and specific kinase inhibitors.</p></div><div><h3>Results</h3><p>In this study, we showed that L48H37 suppressed TPA-stimulated invasive and migratory capacities of NPC cell lines and gave rise to very little cytotoxic responses. Such anti-cancer effect of L48H37 was accompanied with attenuated expression levels and enzymatic activities of matrix metalloproteinase-9 (MMP-9), a pivotal mediator of metastatic processes. In addition, L48H37 interfered with TPA-induced JNK activation, and the treatment of L48H37 combined with a JNK antagonist demonstrated a synergistic effect on restraining TPA-stimulated MMP-9 activity and migration events in NPC cells.</p></div><div><h3>Conclusions</h3><p>Our results revealed that L48H37 impeded the invasive potential of NPC cells via impairment of MMP-9 function and abundance, highlighting possible complementary therapies using curcumin or its effective analogs to manage NPC dissemination.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"159 ","pages":"Article 107038"},"PeriodicalIF":4.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142233833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study 经口机器人手术治疗早期口咽鳞癌后的重返工作和自述吞咽情况：一项回顾性队列研究

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-14 DOI: 10.1016/j.oraloncology.2024.107033

Phillip Staibano , Michael Au , Michael Xie , Michael K. Gupta , James Edward Massey (Ted) Young , Han Zhang

Background

Treatment de-intensification, including transoral robotic surgery (TORS), may outcomes in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). Early return to work (RTW) improves quality of life in oncology patients. Our objective was to compare the RTW time in OPSCC patients undergoing primary TORS or chemoradiotherapy (CRT). We investigated the role of treatment modality on self-reported swallowing function.

Methods

All patients were adults diagnosed with early-stage (T1–2, N0–2) OPSCC and treated via primary TORS or CRT. We performed 1:1 exact case matching based on tumor stage and subsite. We collected RTW outcomes for all patients. We also reported MD Anderson Dysphagia Index (MDADI) scores up to 24 months from the end of treatment. We performed statistical analyses and comparison of RTW and MDADI outcomes based on treatment group.

Results

Overall, 26 patients undergoing primary TORS and 25 undergoing primary CRT were included. We found a significant improvement in RTW in TORS patients compared to CRT (TORS: 54 days (1.8 months), IQR: 30.8; CRT: 164 days (5.4 months), IQR: 109; W=587, p = 9.28e-08) independent of HPV status, tonsillar subsite, and radiotherapy alone. Primary TORS had a 16.2-fold (95 % CI: 5.78–45.5) higher likelihood of returning to work than primary CRT patients. Primary TORS also had better MDADI scores within two years of treatment.

Conclusions

In OPSCC, primary TORS accelerated RTW and improved swallowing when compared to primary CRT. The potential economic advantage of returning to work sooner should be discussed when reviewing treatment options with patients.

背景包括经口机器人手术（TORS）在内的去强化治疗可能会对HPV阳性口咽鳞癌（OPSCC）产生疗效。尽早重返工作岗位（RTW）可提高肿瘤患者的生活质量。我们的目的是比较接受原发性TORS或化疗放疗（CRT）的口咽鳞癌患者的复工时间。方法所有患者均为确诊为早期（T1-2，N0-2）OPSCC 并接受原发性 TORS 或 CRT 治疗的成人。我们根据肿瘤分期和亚部位进行了 1:1 精确病例匹配。我们收集了所有患者的 RTW 结果。我们还报告了自治疗结束后 24 个月内的 MD 安德森吞咽困难指数 (MDADI) 评分。我们根据治疗组别对 RTW 和 MDADI 结果进行了统计分析和比较。结果共纳入了 26 名接受初治 TORS 的患者和 25 名接受初治 CRT 的患者。我们发现，与 CRT 相比，TORS 患者的 RTW 有明显改善（TORS：54天（1.8个月），IQR：30.8；CRT：164天（5.4个月），IQR：109；W=587，P=9.28e-08），不受HPV状态、扁桃体部位和单独放疗的影响。原发性 TORS 患者重返工作岗位的可能性是原发性 CRT 患者的 16.2 倍（95 % CI：5.78-45.5）。结论在 OPSCC 中，与初治 CRT 相比，初治 TORS 加快了复工速度并改善了吞咽功能。在与患者讨论治疗方案时，应讨论尽早重返工作岗位的潜在经济优势。

{"title":"Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study","authors":"Phillip Staibano , Michael Au , Michael Xie , Michael K. Gupta , James Edward Massey (Ted) Young , Han Zhang","doi":"10.1016/j.oraloncology.2024.107033","DOIUrl":"10.1016/j.oraloncology.2024.107033","url":null,"abstract":"<div><h3>Background</h3><p>Treatment de-intensification, including transoral robotic surgery (TORS), may outcomes in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). Early return to work (RTW) improves quality of life in oncology patients. Our objective was to compare the RTW time in OPSCC patients undergoing primary TORS or chemoradiotherapy (CRT). We investigated the role of treatment modality on self-reported swallowing function.</p></div><div><h3>Methods</h3><p>All patients were adults diagnosed with early-stage (T1–2, N0–2) OPSCC and treated via primary TORS or CRT. We performed 1:1 exact case matching based on tumor stage and subsite. We collected RTW outcomes for all patients. We also reported MD Anderson Dysphagia Index (MDADI) scores up to 24 months from the end of treatment. We performed statistical analyses and comparison of RTW and MDADI outcomes based on treatment group.</p></div><div><h3>Results</h3><p>Overall, 26 patients undergoing primary TORS and 25 undergoing primary CRT were included. We found a significant improvement in RTW in TORS patients compared to CRT (TORS: 54 days (1.8 months), IQR: 30.8; CRT: 164 days (5.4 months), IQR: 109; W=587, p = 9.28e-08) independent of HPV status, tonsillar subsite, and radiotherapy alone. Primary TORS had a 16.2-fold (95 % CI: 5.78–45.5) higher likelihood of returning to work than primary CRT patients. Primary TORS also had better MDADI scores within two years of treatment.</p></div><div><h3>Conclusions</h3><p>In OPSCC, primary TORS accelerated RTW and improved swallowing when compared to primary CRT. The potential economic advantage of returning to work sooner should be discussed when reviewing treatment options with patients.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"159 ","pages":"Article 107033"},"PeriodicalIF":4.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary on “Predictive value of CXCL1+_FAP+ phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients” 关于 "局部区域晚期鼻咽癌患者 CAF 中 CXCL1+_FAP+ 表型对远处转移的预测价值及其与 PD-L1 表达的相关性 "的评论文章

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-14 DOI: 10.1016/j.oraloncology.2024.107036

Siva Dharshini Rajathirajan

引用次数: 0

Commentary on “Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.” 关于 "高危 EBV 株系对鼻咽癌基因表达的影响 "的评论。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-14 DOI: 10.1016/j.oraloncology.2024.107037

Siva Dharshini Rajathirajan

引用次数: 0

Authors reply to the comment on: Association of sarcopenia with oncologic outcomes of primary treatment among patients with oral cavity cancer: A systematic review and meta-analysis 作者回复评论肌肉疏松症与口腔癌患者初治结果的关系：系统回顾与荟萃分析

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-12 DOI: 10.1016/j.oraloncology.2024.107017

Jeffrey P. Graves , Ghazal S. Daher , Megan M.J. Bauman , Eric J. Moore , Kendall K. Tasche , Daniel L. Price , Kathryn M. Van Abel

引用次数: 0

Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients 唾液 DNA 甲基化衍生的生物老化估计值、细胞频率和蛋白质表达可预测头颈部癌症患者口腔黏膜炎的严重程度和存活率

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-09-12 DOI: 10.1016/j.oraloncology.2024.107030

Chris P. Verschoor , Stacey A. Santi , Ravi Singh , Sujeenthar Tharmalingam , Christopher Thome , Deborah P. Saunders

Background

Oral mucositis is a painful and debilitating condition that occurs in the majority of head and neck cancer patients receiving radiation and/or chemotherapy. While some patient and treatment related factors are known to contribute to the incidence and severity of disease, reliable biomarkers remain elusive. In the following study, we investigated the association of salivary DNA methylation derived biological aging, cellular frequency and protein concentration measures with the severity of oral mucositis and overall survival in a cohort of head and neck cancer (HNC) patients (n = 103).

Methods

DNA methylation profiling was performed on saliva samples obtained prior to treatment. Biological aging measures included Horvath2, PhenoAge, FitAge and GrimAge, and cellular frequency included epithelial and specific immune cell populations.

Results

Severe mucositis (i.e. grade 3 or 4) occurred in nearly half of patients. For malignant HNC patients (n = 84), every 1-SD increase in GrimAge was associated with 2.62-times risk of severe mucositis (95 % CI: 1.38, 5.57), while a 1-SD increase in monocyte frequency was associated with a decreased risk (OR [95 %CI]: 0.40 [0.18, 0.80]). Over a median follow-up of 53 months, 39 of 103 participants died. Six protein scores (TNFSF14, GCSF, MATN3, GDF8, nCDase, TNF-β) were associated with survival at q < 0.15.

Conclusion

We provide evidence that the risk-related biological aging measure GrimAge may be a useful predictor of mucositis severity in HNC patients. Salivary monocyte frequency may be protective against mucositis, and this measure could be used as a predictive biomarker while also providing clues into the pathobiology of the disease.

背景大多数接受放疗和/或化疗的头颈部癌症患者都会出现口腔粘膜炎，这是一种令人痛苦和虚弱的疾病。虽然已知一些与患者和治疗相关的因素会导致疾病的发生率和严重程度，但可靠的生物标志物仍然难以捉摸。在接下来的研究中，我们调查了一组头颈癌（HNC）患者（n = 103）唾液 DNA 甲基化衍生的生物老化、细胞频率和蛋白质浓度测量与口腔黏膜炎严重程度和总生存期的关系。生物老化测量包括 Horvath2、PhenoAge、FitAge 和 GrimAge，细胞频率包括上皮细胞群和特定免疫细胞群。对于恶性 HNC 患者（n = 84），GrimAge 每增加 1 个标准差，发生严重粘膜炎的风险就会增加 2.62 倍（95 % CI：1.38, 5.57），而单核细胞频率每增加 1 个标准差，发生严重粘膜炎的风险就会降低（OR [95 %CI]：0.40 [0.18, 0.80]）。在中位 53 个月的随访期间，103 名参与者中有 39 人死亡。六项蛋白质评分（TNFSF14、GCSF、MATN3、GDF8、nCDase、TNF-β）与存活率相关（q < 0.15）。结论我们提供的证据表明，与风险相关的生物老化测量 GrimAge 可能是预测 HNC 患者粘膜炎严重程度的有效指标。唾液单核细胞频率可能对粘膜炎有保护作用，该指标可用作预测性生物标志物，同时还能提供疾病病理生物学的线索。

{"title":"Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients","authors":"Chris P. Verschoor , Stacey A. Santi , Ravi Singh , Sujeenthar Tharmalingam , Christopher Thome , Deborah P. Saunders","doi":"10.1016/j.oraloncology.2024.107030","DOIUrl":"10.1016/j.oraloncology.2024.107030","url":null,"abstract":"<div><h3>Background</h3><p>Oral mucositis is a painful and debilitating condition that occurs in the majority of head and neck cancer patients receiving radiation and/or chemotherapy. While some patient and treatment related factors are known to contribute to the incidence and severity of disease, reliable biomarkers remain elusive. In the following study, we investigated the association of salivary DNA methylation derived biological aging, cellular frequency and protein concentration measures with the severity of oral mucositis and overall survival in a cohort of head and neck cancer (HNC) patients (n = 103).</p></div><div><h3>Methods</h3><p>DNA methylation profiling was performed on saliva samples obtained prior to treatment. Biological aging measures included Horvath2, PhenoAge, FitAge and GrimAge, and cellular frequency included epithelial and specific immune cell populations.</p></div><div><h3>Results</h3><p>Severe mucositis (i.e. grade 3 or 4) occurred in nearly half of patients. For malignant HNC patients (n = 84), every 1-SD increase in GrimAge was associated with 2.62-times risk of severe mucositis (95 % CI: 1.38, 5.57), while a 1-SD increase in monocyte frequency was associated with a decreased risk (OR [95 %CI]: 0.40 [0.18, 0.80]). Over a median follow-up of 53 months, 39 of 103 participants died. Six protein scores (TNFSF14, GCSF, MATN3, GDF8, nCDase, TNF-β) were associated with survival at q < 0.15.</p></div><div><h3>Conclusion</h3><p>We provide evidence that the risk-related biological aging measure GrimAge may be a useful predictor of mucositis severity in HNC patients. Salivary monocyte frequency may be protective against mucositis, and this measure could be used as a predictive biomarker while also providing clues into the pathobiology of the disease.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"159 ","pages":"Article 107030"},"PeriodicalIF":4.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1368837524003488/pdfft?md5=3d0ef3c9a4dfc974ff9e0e4b70933cfd&pid=1-s2.0-S1368837524003488-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Oral oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀